Ohtake, S., Kawahara, T., Kasahara, R., Ito, H., Osaka, K., Hattori, Y., . . . Uemura, H. (2016). Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. Biomed Res Int.
Chicago ZitierstilOhtake, Shinji, et al. "Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy." Biomed Res Int 2016.
MLA ZitierstilOhtake, Shinji, et al. "Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy." Biomed Res Int 2016.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.